Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Sharon Quimby and American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sharon Quimby and American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

May 2025 Recall: Topics on Myasthenia Gravis

58:16
 
Share
 

Manage episode 480169758 series 113518
Content provided by Sharon Quimby and American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sharon Quimby and American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques.

Podcast links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for MG in the US

Article links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States

Disclosures can be found at Neurology.org.

  continue reading

1228 episodes

Artwork
iconShare
 
Manage episode 480169758 series 113518
Content provided by Sharon Quimby and American Academy of Neurology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sharon Quimby and American Academy of Neurology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

The May 2025 recall features four previously posted episodes on myasthenia gravis. The first episode has Dr. Fredrik Piehl discussing rituximab for new-onset generalized MG. In the second episode, Dr. Vera Bril explores the potential use of immunoglobulin as a corticosteroid-sparing agent in MG patients. The third episode features Dr. Ali A. Habib discussing trends in hospital admissions and in-hospital mortality for adult MG patients. The series concludes with Dr. Jennifer Morganroth addressing the increase in thymectomy procedures post-MGTX trial, disparities in access to these surgeries among different demographic groups, and the rise of minimally invasive surgical techniques.

Podcast links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality from MG Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for MG in the US

Article links:

Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis

Randomized Double-Blind Placebo-Controlled Trial of the Corticosteroid-Sparing Effects of Immunoglobulin in Myasthenia Gravis

Hospitalizations and Mortality From Myasthenia Gravis

Trends and Disparities in the Utilization of Thymectomy for Myasthenia Gravis in the United States

Disclosures can be found at Neurology.org.

  continue reading

1228 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play